Related Experiment Videos
Adaptive design improvements in the continual reassessment method for phase I studies
1Medtronic Inc., Minneapolis, Minnesota 55421, USA.
Statistics in Medicine
|July 10, 1999
Summary
This study refines the continual reassessment method (CRM) for phase I oncology trials. New adaptive designs allow earlier trial stopping based on accumulating data, improving efficiency while maintaining estimation accuracy for the maximum tolerated dose (MTD).
Area of Science:
- Biostatistics
- Clinical Trial Design
- Oncology Research
Background:
- The continual reassessment method (CRM) efficiently uses available data in phase I studies.
- Practical difficulties have limited the clinical adoption of CRM despite enhancements.
Purpose of the Study:
- To introduce and evaluate further refinements to the CRM for phase I oncology trials.
- To develop adaptive designs that allow for earlier trial cessation.
Main Methods:
- Proposed adaptive designs incorporate stopping rules based on the width of the posterior probability interval for the maximum tolerated dose (MTD).
- A simulation study evaluated five stopping rules under varying prior knowledge states of the MTD.
Main Results:
- The refined adaptive designs maintain the CRM's robust estimation capabilities for the MTD.
- The proposed methods offer the potential for earlier termination of phase I clinical trials.
Conclusions:
- These adaptive CRM designs enhance the practicality of phase I oncology trials.
- Earlier stopping can lead to more efficient drug development processes.